Prof Benjamin Besse (Institut Gustave Roussy, Villejuif, France) and Dr Alex Spira (Virginia Cancer Specialists Research Institute, Fairfax, USA) discuss the latest developments in EGFR-mutated non-small cell lung cancer (NSCLC) presented at ASCO 2020.
Prof Besse begins by outlining the results of ADARURA study, which investigated the use of osimertinib as an adjuvant therapy in patients with stage IB-IIIA EGFR mutation-positive (EGFRm) NSCLC after complete tumour resection. Dr Spira states that the disease-free survival (DFS) achieved in these patients is profound and potentially practice-changing, but acknowledges there is some debate surrounding the immaturity of the overall survival data.
The experts also highlight the latest results of CHRYSALLIS trial, which is an ongoing phase I trial investigating amivantamab, an anti-EGFR-MET bispecific antibody, in NSCLC patients with EGFR exon 20 mutations.
Prof Besse and Dr Spira conclude by discussing the outcomes in patients with advanced NSCLC and PDL-1 expression treated with immune checkpoint inhibitor monotherapy, along with the evolving role of liquid biopsies.
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).